NAALADL2 and prostate cancer: In the ICGC cohorts, individuals with somatic single-base alterations in NAALADL2 also associated with reduced disease-free survival in a combined ICGC cohort as well as associating with reduced disease-free and overall survival in an early onset prostate cancer cohort (ICGC EOPC, Denmark).